LEO Pharma A/S announced that the findings of the DELTA 1 and DELTA 2 phase 3 clinical trials for delgocitinib cream have been published in the peer-reviewed periodical The Lancet. This is the first time The Lancet has published data on an investigational topical pan-Janus kinase (JAK) inhibitor for the treatment of moderate to severe CHE, according to a press release.
The publication summarizes the randomized, double-blinded, multi-center vehicle-controlled clinical phase 3 DELTA 1 and DELTA 2 trials. These trials evaluated the safety and efficacy of investigational delgocitinib cream compared to cream vehicle in adult patients with moderate to severe CHE who had inadequate response to, or for whom topical corticosteroids were medically inadvisable. Delgocitinib cream is currently under investigation and has not been approved by any health authority.
“Having the DELTA 1 and 2 trial results featured in one of the most highly regarded peer-reviewed medical journals in the world is a vital step on our mission to raise awareness and develop potential new treatment options for those living with CHE,” Kreesten Meldgaard Madsen, Chief Development Officer for LEO Pharma, said in the press release. “The publication of our research in The Lancet is a proud milestone for everyone who has worked tirelessly on the DELTA 1 and 2 trials, and proves LEO Pharma’s commitment to pioneering new potential treatment options for those living with skin conditions. We are excited to share this analysis with the broader scientific and medical community to
help drive further research advances for CHE.”
Primary and all secondary endpoints were met in both DELTA 1 and DELTA 2 trials.